Genomic analysis of atypical fibroxanthoma

Kevin Lai, Catherine A. Harwood, Karin J. Purdie, Charlotte M. Proby, Irene M. Leigh, Namita Ravi, Thaddeus W. Mully, Lionel Brooks, Priscilla M. Sandoval, Michael D. Rosenblum, Sarah T. Arron (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    23 Citations (Scopus)
    265 Downloads (Pure)


    Atypical fibroxanthoma (AFX), is a rare type of skin cancer affecting older individuals with sun damaged skin. Since there is limited genomic information about AFX, our study seeks to improve the understanding of AFX through whole-exome and RNA sequencing of 8 matched tumor-normal samples. AFX is a highly mutated malignancy with recurrent mutations in a number of genes, including COL11A1, ERBB4, CSMD3, and FAT1. The majority of mutations identified were UV signature (C>T in dipyrimidines). We observed deletion of chromosomal segments on chr9p and chr13q, including tumor suppressor genes such as KANK1 and CDKN2A, but no gene fusions were found. Gene expression profiling revealed several biological pathways that are upregulated in AFX, including tumor associated macrophage response, GPCR signaling, and epithelial to mesenchymal transition (EMT). To further investigate the presence of EMT in AFX, we conducted a gene expression meta-analysis that incorporated RNA-seq data from dermal fibroblasts and keratinocytes. Ours is the first study to employ high throughput sequencing for molecular profiling of AFX. These data provide valuable insights to inform models of carcinogenesis and additional research towards tumor-directed therapy.

    Original languageEnglish
    Article numbere0188272
    Pages (from-to)1-15
    Number of pages15
    JournalPLoS ONE
    Issue number11
    Publication statusPublished - 15 Nov 2017


    Dive into the research topics of 'Genomic analysis of atypical fibroxanthoma'. Together they form a unique fingerprint.

    Cite this